Globally, over many years, one of the top drugs for the treatment of HIV/AIDS is Genvoya, marketed by Gilead. In 2023, Genvoya generated some two billion U.S. dollars in revenue. Biktarvy, also marketed by Gilead, was the best-selling HIV/AIDS treatment and generated around 11.9 billion U.S. dollars in revenue. Gilead is the drug manufacturer most specialized in developing drugs for the treatment of HIV/AIDS.
HIV/AIDS cases worldwide
HIV is a virus that attacks the immune system, leading to an increased risk of infections and can lead to death. HIV/AIDS first appeared in global populations in the 1980s. According to current estimates, the prevalence of HIV is highest in low and middle income countries. Eswatini, followed by Lesotho, had the highest rates of HIV infections in 2022. The number of new HIV infections by world region is highest among residents of Eastern and Southern Africa.
Access to HIV/AIDS treatment
Effective treatment for HIV was not available until the early 1990s. Access to therapy has increased since the early 2000s, and as of 2022 there were approximately 30 million people that had access to antiretroviral therapy. Among countries around the world, Uganda, India and Kenya, to name a few, have the lowest rates of access to antiretroviral medications for the treatment of HIV/AIDS. Meanwhile, trends indicate that children living with HIV in Asia or the Pacific have some of the highest rates of access to antiretroviral therapy globally.
https://www.mordorintelligence.com/privacy-policyhttps://www.mordorintelligence.com/privacy-policy
The Prophylactic HIV Drugs Market Report is Segmented by Drug (Tenofovir, Emtricitabine, and Other Drugs), Dosage Form (Oral and Topical), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers Market Sizes and Forecasts in Terms of Value (USD) for the Above Segments.
https://www.transparencymarketresearch.com/privacy-policy.htmlhttps://www.transparencymarketresearch.com/privacy-policy.html
HIV Drugs Market Overview
Attribute | Detail |
---|---|
Market Drivers |
|
Regional Analysis
Attribute | Detail |
---|---|
Leading Region | North America |
Global HIV Drugs Market Snapshot
Attribute | Detail |
---|---|
Market Size in 2023 | US$ 28.6 Bn |
Market Forecast (Value) in 2034 | US$ 47.5 Bn |
Growth Rate (CAGR) | 4.7% |
Forecast Period | 2024-2034 |
Historical Data Available for | 2020-2022 |
Quantitative Units | US$ Bn for Value |
Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
Competition Landscape |
|
Format | Electronic (PDF) + Excel |
Market Segmentation |
|
Regions Covered |
|
Countries Covered |
|
Companies Profiled |
|
Customization Scope | Available Upon Request |
Pricing | Available Upon Request |
https://www.cognitivemarketresearch.com/privacy-policyhttps://www.cognitivemarketresearch.com/privacy-policy
According to Cognitive Market Research, the global HIV drugs market size will be USD 35425.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.80% from 2024 to 2031.
North America held the major market share for more than 40% of the global revenue with a market size of USD 14170.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.0% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 10627.56 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 8147.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 1771.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 708.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.
The multi-class combination drugs held the highest HIV drugs market revenue share in 2024.
Market Dynamics of HIV drugs Market
Key Drivers for HIV drugs Market
Rising number of HIV-positive individuals to Increase the Demand Globally
The HIV drugs market has experienced growth due to rising number of HIV-positive individuals. As global HIV prevalence increases due to factors like higher transmission rates and improved diagnostic capabilities, demand for effective antiretroviral therapies (ART) surges. This growing patient base necessitates the continuous development and supply of innovative drugs to manage HIV effectively, reduce viral loads, and improve quality of life. Increased awareness and testing also contribute to higher diagnosed cases, further expanding the market for HIV treatments and driving pharmaceutical companies to invest in research and development.
Innovations in HIV diagnostic tools to Propel Market Growth
The HIV drugs market has witnessed steady growth, driven by innovations in HIV diagnostic tools. Advances include rapid, point-of-care tests that deliver results within minutes, improving patient access and reducing diagnostic delays. Integrated technologies, such as multiplex assays, detect multiple markers simultaneously, increasing diagnostic accuracy. Additionally, digital platforms for data management streamline monitoring and personalized treatment plans. These innovations not only improve patient outcomes but also stimulate demand for more effective HIV treatments and management solutions, fostering market growth.
Restraint Factor for the HIV drugs Market
High cost of HIV treatment to Limit the Sales
The high costs of HIV medications constrain the growth of HIV drugs market. It involves expensive medications that can be unaffordable for many patients, especially in low-income regions. The costs are compounded by the need for lifelong treatment, regular monitoring, and potential side effects management, which further burdens healthcare systems and patients. This financial barrier limits access to effective treatment, leading to disparities in care and hindering efforts to control the HIV epidemic globally.
Impact of Covid-19 on the HIV drugs Market
The Covid-19 significantly impacted the market by disrupting supply chains, leading to delays in drug production and distribution, increasing lockdowns and restrictions. Additionally, the focus on COVID-19 diverted resources away from HIV programs, affecting drug availability and patient adherence. However, the pandemic also accelerated the adoption of telemedicine and digital health solutions, which helped maintain patient care continuity. Overall, the pandemic highlighted the need for resilient healthcare systems in managing chronic diseases. Introduction of the HIV drugs Market
HIV drugs are medications used to treat Human Immunodeficiency Virus (HIV) infection. They work by suppressing the virus, preventing its replication, and protecting the immune system. These drugs are typically used in combination as antiretroviral therapy (ART) to reduce viral load, improve patient outcomes, and prevent the progression to AIDS. The rising number of HIV-positive individuals, advancemnets in drug development, increasing government initiatives and funding, increased aw...
https://www.promarketreports.com/privacy-policyhttps://www.promarketreports.com/privacy-policy
The HIV Drugs Market is segmented based on type and end-user. By type, the market is segmented into nucleoside, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, fusion inhibitors, and CCR5 antagonists. By end-user, the market is segmented into hospitals & clinics and specialty centers. Recent developments include: July 2021:To make darunavir paired with ritonavir (DRV/r) as a second-line medication for HIV patients living in low and medium-income countries, Unitaid and Clinton Health Access Initiative, Inc. (CHAI) announced a pricing agreement with pharmaceutical company Hetero Labs LTD. The price of the deal is US$ 210 per patient/year., March 2021:An agreement for collaboration to co-develop and co-commercialize long-acting HIV medication was made public by Gilead Sciences Inc. and Merck. To create a two-drug HIV treatment regimen, the firms want to combine lenacapavir, an experimental capsid inhibitor from Gilead, with islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor from Merck.. Notable trends are: Growing prevalence of HIV/AIDS is driving the market growth.
https://www.futuremarketinsights.com/privacy-policyhttps://www.futuremarketinsights.com/privacy-policy
The Prophylactic HIV Drugs Market will expand to reach USD 54.7 billion during 2035 from USD 35.2 billion in 2025 due to an anticipated 4.5% CAGR throughout the forecast period.
Metric | Value |
---|---|
Market Size (2025E) | USD 35.2 Billion |
Market Value (2035F) | USD 54.7 Billion |
CAGR (2025 to 2035) | 4.5% |
Country-wise Insights
Country | CAGR (2025 to 2035) |
---|---|
United States | 4.7% |
Country | CAGR (2025 to 2035) |
---|---|
United Kingdom | 4.2% |
Country | CAGR (2025 to 2035) |
---|---|
European Union | 4.5% |
Country | CAGR (2025 to 2035) |
---|---|
Japan | 4.3% |
Country | CAGR (2025 to 2035) |
---|---|
South Korea | 4.4% |
Prophylactic HIV Drugs- Segmentation Outlook
Drug Class | Market Share |
---|---|
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI) | 63.5% |
Distribution Channel | Market Share |
---|---|
Hospital Pharmacies | 45.8% |
Competitive Outlook
Company Name | Estimated Market Share (%) |
---|---|
Gilead Sciences | 35-40% |
ViiV Healthcare | 25-30% |
Merck & Co., Inc. | 15-20% |
Johnson & Johnson | 5-10% |
Other Companies (combined) | 10-15% |
https://www.imarcgroup.com/privacy-policyhttps://www.imarcgroup.com/privacy-policy
The North America HIV drugs market size was valued at USD 23.84 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 36.91 Billion by 2033, exhibiting a CAGR of 4.78% from 2025-2033. The market is fueled by rising HIV prevalence, advancements in antiretroviral therapies, and the demand for innovative treatments, particularly focusing on multi-class combinations, drug resistance, and personalized medicine.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
| USD 23.84 Billion |
Market Forecast in 2033
| USD 36.91 Billion |
Market Growth Rate (2025-2033) | 4.78% |
IMARC Group provides an analysis of the key trends in each segment of the North America HIV drugs market, along with forecasts at the country and regional levels from 2025-2033. The market has been categorized based on drug class and distribution channel.
https://www.marketreportanalytics.com/privacy-policyhttps://www.marketreportanalytics.com/privacy-policy
The global anti-retroviral (ARV) drugs market, valued at approximately $25 billion in 2025, is projected to experience steady growth, exhibiting a compound annual growth rate (CAGR) of 4.00% from 2025 to 2033. This growth is fueled by several key drivers, including the increasing prevalence of HIV/AIDS globally, particularly in developing nations where access to treatment remains a challenge. Ongoing research and development efforts are leading to the introduction of newer, more effective ARV drugs with improved tolerability and reduced side effects, further driving market expansion. The emergence of drug-resistant strains of HIV necessitates the development and adoption of new treatment regimens, presenting both a challenge and an opportunity for pharmaceutical companies. Market segmentation reveals a diverse landscape, with protease inhibitors, integrase inhibitors, and multi-class combination products representing significant segments, reflecting the evolving treatment strategies and the increasing complexity of managing HIV infection. The market's growth, however, faces restraints such as the potential for generic competition and price pressures, especially in price-sensitive markets. The successful implementation of public health initiatives and improved access to affordable ARV drugs in underserved regions will significantly influence the market's future trajectory. The regional distribution of the ARV drug market shows significant variations. North America and Europe are expected to maintain substantial market shares due to high healthcare expenditure and advanced healthcare infrastructure. However, the Asia-Pacific region, particularly countries like India and China, is anticipated to experience significant growth owing to increasing HIV prevalence and rising disposable incomes. The Middle East and Africa, while facing challenges in access to healthcare, also present a significant growth potential given the high prevalence of HIV/AIDS in some regions. Key players in the market, including AbbVie, Gilead Sciences, Merck, and Johnson & Johnson, continue to invest heavily in research and development, seeking to innovate and maintain market leadership through the development of novel therapies and improved treatment approaches. This competitive landscape underscores the importance of strategic partnerships, distribution networks, and pricing strategies for successful market penetration. Recent developments include: In September 2022, Merck reported initiating a new phase 3 clinical trial evaluating once-daily oral islatravir for HIV-1 infection., In August 2022, Gilead received the global regulatory approval of Sunlenca (Lenacapavir), the twice-yearly HIV treatment option.. Key drivers for this market are: Rising Burden of HIV, Increasing Investment in R&D; Increase in Availability of Novel Drugs with Better Efficacy. Potential restraints include: Rising Burden of HIV, Increasing Investment in R&D; Increase in Availability of Novel Drugs with Better Efficacy. Notable trends are: Multi-class Combination Product Segment is Expected to Register a Significant Growth Over the Forecast Period..
https://www.marknteladvisors.com/privacy-policyhttps://www.marknteladvisors.com/privacy-policy
The Africa HIV Drugs Market is projected to expand steadily at a rate of approximately 8.20% CAGR from 2024 to 2030. By Drug Class, By Distribution Channel
https://dataintelo.com/privacy-and-policyhttps://dataintelo.com/privacy-and-policy
The global HIV therapeutics market is poised for substantial growth, with the market size projected to reach approximately USD 45 billion by 2032, up from USD 30 billion in 2023, reflecting a compound annual growth rate (CAGR) of around 4.5%. This growth is driven by various factors, including advancements in antiretroviral therapies, increased awareness and diagnosis of HIV, and the continued introduction of novel drug combinations. The market is further propelled by global health initiatives and funding that aim to reduce the incidence of HIV and improve the quality of life for those living with the virus.
One of the key growth factors for the HIV therapeutics market is the ongoing innovation in drug development. Pharmaceutical companies continue to invest heavily in research and development to create more effective, less toxic, and easier-to-administer HIV treatments. The advent of long-acting injectable antiretrovirals and the development of combination therapies that reduce the pill burden on patients are significant advancements. These innovations not only improve adherence to treatment regimens but also enhance the overall effectiveness of HIV management, thereby driving the market forward.
Furthermore, the increasing prevalence of HIV, particularly in developing regions, is a major driver of market growth. With millions of individuals affected by HIV worldwide, there is a high demand for effective treatments that can manage the virus and prevent its transmission. Global health organizations and governments are investing in programs to expand access to HIV testing and treatment, creating a favorable environment for the growth of the HIV therapeutics market. These efforts are complemented by educational campaigns aimed at reducing stigma and encouraging individuals to seek testing and treatment.
The growing emphasis on pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) as preventive measures against HIV transmission is another factor boosting the market. PrEP and PEP have gained traction as effective strategies for reducing the risk of HIV infection in high-risk populations. As awareness about these preventive measures increases, so does the demand for the therapies that facilitate them. This shift in focus towards prevention, alongside treatment, is expanding the scope of the HIV therapeutics market.
The development of HIV Vaccines represents a promising frontier in the fight against the virus. Unlike therapeutic approaches that manage the infection, vaccines aim to prevent it altogether. Researchers are focusing on creating vaccines that can elicit strong immune responses capable of neutralizing the virus before it establishes infection. The progress in this area has been bolstered by advances in understanding the virus's structure and immune evasion tactics. While challenges remain, such as the virus's high mutation rate, the potential impact of a successful vaccine could be transformative, significantly reducing new infections and altering the landscape of HIV prevention strategies.
Regionally, North America holds a significant share of the HIV therapeutics market, driven by high healthcare spending, strong healthcare infrastructure, and major investments in HIV research. However, the Asia Pacific region is expected to exhibit the fastest growth, with a CAGR surpassing other regions. This growth is fueled by increasing HIV prevalence, expanding healthcare access, and rising awareness about HIV treatment and prevention strategies. Initiatives by governments and NGOs in countries like India and China to enhance treatment accessibility are also contributing to market expansion in this dynamic region.
The drug class segment is a crucial component of the HIV therapeutics market, encompassing various categories such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors, integrase inhibitors, and others. NRTIs form the backbone of antiretroviral therapy and have been instrumental in improving the survival and quality of life for HIV patients. They work by blocking the reverse transcriptase enzyme, essential for the replication of the virus, thus suppressing viral load. Despite their efficacy, NRTIs are often associated with side effects, leading to the development of newer, less toxic alternatives.
Non-nucleoside reverse transcrip
https://www.marketresearchforecast.com/privacy-policyhttps://www.marketresearchforecast.com/privacy-policy
Key drivers for this market are: “Application of cost-effective materials for manufacturing is likely to propel the global microfluidic devices market”. Potential restraints include: Lack of Diagnosis and Treatment in Developing Countries to Limit the Demand for Wound Dressings . Notable trends are: Shift of Healthcare Providers from Medication to Electrical Stimulation for Treatment of Neurological Disorders to Fuel the Market.
https://www.mordorintelligence.com/privacy-policyhttps://www.mordorintelligence.com/privacy-policy
The HIV/AIDS Diagnostics Market Report is Segmented by Product (Consumables, Instruments, Software & Services), Test Type (Antibody Tests, Viral Load Tests, CD4 Tests, Others), Technology (Immunoassay, Molecular Diagnostics, and More), End User (Hospitals, Diagnostic Laboratories, At-Home Settings, Others), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).
https://www.consegicbusinessintelligence.com/privacy-policyhttps://www.consegicbusinessintelligence.com/privacy-policy
The global HIV drugs market size is forecasted to grow with a CAGR of 5.7% between 2024 and 2031, reaching a valuation of USD 52,504.67 million by 2031 from USD 33,807.33 million in 2023.
https://www.marketresearchforecast.com/privacy-policyhttps://www.marketresearchforecast.com/privacy-policy
The Hiv/Aids Drugs Market size was valued at USD 28.79 USD Billion in 2023 and is projected to reach USD 110.60 USD Billion by 2032, exhibiting a CAGR of 21.2 % during the forecast period. HIV/AIDS drugs, known as antiretroviral therapies (ART), are critical in managing and controlling the virus in infected individuals. ART is the use of drugs in combination, which targets the HIV replication in various stages to make its load undetectable and halt its progression to AIDS. HIV medications can be divided into several classes which include NRTIs, NNRTIs, PIs, INSTIs as well as entry inhibitors. Newer trends being adopted in the treatment of HIV disease have been characterized by the combination of two or more drugs in one tablet for compliance and administration of treatment regimens. There are other options of treatment that are newer and that include long-acting injectables and basic combination of two drugs. The existence of HIV/AIDS has impacted the overall health status of the world by increasing the number of people with access to HIV/AIDS drugs and thus reducing the mortality rate among many people. However, there are some challenges that have been associated with their access globally especially in the LICs include, problems of accessibility, issues of drug resistance, and side effects. Key drivers for this market are: Increasing Public Awareness for Safer Medicines to Stimulate Market Value. Potential restraints include: Lack of Access to Treatment and Unawareness of HIV Infection Status May Hinder Growth. Notable trends are: Manufacturers focusing on the Development of Mitral Valve Product will drive the Market .
https://www.expertmarketresearch.com/privacy-policyhttps://www.expertmarketresearch.com/privacy-policy
The United States HIV drugs market is estimated to expand at a CAGR of 4.30% in the forecast period of 2025-2034.
https://www.marketreportanalytics.com/privacy-policyhttps://www.marketreportanalytics.com/privacy-policy
The size of the Hiv Drugs market was valued at USD XXX billion in 2024 and is projected to reach USD XXX billion by 2033, with an expected CAGR of 5.02% during the forecast period.HIV drugs are those drugs used in the treatment and management of human immunodeficiency virus (HIV) infection. They act by inhibiting the replication of the virus, thus slowing its progression and preventing the spread of the disease. The HIV drugs market comprises a vast number of antiretroviral drugs, such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and entry inhibitors. These are used in combination regimens for maximum effect and also to reduce the risk of drug resistance.
https://www.marketresearchintellect.com/privacy-policyhttps://www.marketresearchintellect.com/privacy-policy
Discover the latest insights from Market Research Intellect's Pediatric HIV Infection Treatment Market Report, valued at USD 1.2 billion in 2024, with significant growth projected to USD 2.0 billion by 2033 at a CAGR of 7.3% (2026-2033).
https://www.expertmarketresearch.com/privacy-policyhttps://www.expertmarketresearch.com/privacy-policy
The HIV drug market size attained a value of USD 33.54 Billion in 2024. The market is anticipated to grow at a CAGR of 4.50% during the forecast period of 2025-2034 to attain a value of USD 52.09 Billion by 2034.
https://www.marketreportanalytics.com/privacy-policyhttps://www.marketreportanalytics.com/privacy-policy
The prophylactic HIV drugs market, valued at approximately $XX million in 2025, is projected to experience steady growth, driven by increasing HIV prevalence, particularly in developing nations, coupled with expanding awareness regarding pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). The market's 4.10% CAGR from 2019-2033 indicates a consistent demand for these life-saving medications. Key growth drivers include government initiatives promoting wider access to PrEP and PEP, increased research and development efforts focusing on novel drug formulations (e.g., long-acting injectables), and a growing understanding of the importance of preventing HIV transmission. The market segmentation by drug (Tenofovir, Emtricitabine, and other drugs) and dosage form (oral and topical) reflects diverse treatment approaches tailored to individual needs and preferences. While the market faces challenges such as drug resistance and the high cost of treatment, especially in low-income countries, ongoing advancements in drug development and increasing affordability are poised to mitigate these restraints in the coming years. The competition among established pharmaceutical giants like Gilead Sciences, AbbVie, and Johnson & Johnson, alongside the contributions of generic manufacturers, is expected to fuel further market expansion, promoting both innovation and accessibility. Major regional markets include North America (particularly the United States), Europe, and Asia Pacific, reflecting varying levels of HIV prevalence and healthcare infrastructure. The market's robust growth prospects are contingent upon continued investment in public health initiatives, improved access to healthcare in underserved communities, and the ongoing development of safer and more effective prophylactic therapies. This growth will likely be seen across all segments, with oral formulations remaining dominant due to established usage but long-acting injectables capturing a growing market share driven by improved patient compliance. The inclusion of a broader range of drug options in PrEP and PEP regimens will also positively impact market growth. Recent developments include: June 2024: Gilead Sciences Inc. funded two studies on long-acting human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) through the HIV Prevention Trials Network (HPTN). The studies focuses on a long-acting version of lenacapavir administered every six months., March 2024: ViiV Healthcare reported the positive findings from its phase I study of an investigational formulation of cabotegravir, known as cabotegravir ultra long-acting (CAB-ULA), which can be dosed at intervals of at least four months.. Key drivers for this market are: High Prevalence of HIV/AIDS, Increasing Government Initiatives; Increasing R&D Activities. Potential restraints include: High Prevalence of HIV/AIDS, Increasing Government Initiatives; Increasing R&D Activities. Notable trends are: The Oral Drug Forms Segment is Expected to Hold a Significant Share During the Forecast Period.
https://www.promarketreports.com/privacy-policyhttps://www.promarketreports.com/privacy-policy
The US HIV Diagnosis Treatment Market can be segmented by product type into:Antiretroviral drugsHIV testing kitsPrevention toolsCounseling and support servicesThe antiretroviral drug market is the largest segment of the US HIV Diagnosis Treatment Market, and it is expected to continue to grow over the forecast period. Antiretroviral drugs are used to suppress the HIV virus and improve the health of people living with HIV. Notable trends are: Growing pet ownership is driving the market growth.
Globally, over many years, one of the top drugs for the treatment of HIV/AIDS is Genvoya, marketed by Gilead. In 2023, Genvoya generated some two billion U.S. dollars in revenue. Biktarvy, also marketed by Gilead, was the best-selling HIV/AIDS treatment and generated around 11.9 billion U.S. dollars in revenue. Gilead is the drug manufacturer most specialized in developing drugs for the treatment of HIV/AIDS.
HIV/AIDS cases worldwide
HIV is a virus that attacks the immune system, leading to an increased risk of infections and can lead to death. HIV/AIDS first appeared in global populations in the 1980s. According to current estimates, the prevalence of HIV is highest in low and middle income countries. Eswatini, followed by Lesotho, had the highest rates of HIV infections in 2022. The number of new HIV infections by world region is highest among residents of Eastern and Southern Africa.
Access to HIV/AIDS treatment
Effective treatment for HIV was not available until the early 1990s. Access to therapy has increased since the early 2000s, and as of 2022 there were approximately 30 million people that had access to antiretroviral therapy. Among countries around the world, Uganda, India and Kenya, to name a few, have the lowest rates of access to antiretroviral medications for the treatment of HIV/AIDS. Meanwhile, trends indicate that children living with HIV in Asia or the Pacific have some of the highest rates of access to antiretroviral therapy globally.